Pomerantz Law Firm Investigates Potential Securities Fraud at ImmunityBio, Inc. Amidst Recent Stock Drop

Investor Alert: Pomerantz Law Firm Investigates ImmunityBio, Inc.

Pomerantz LLP, a leading law firm known for its expertise in corporate litigation, has announced an investigation concerning ImmunityBio, Inc. (NASDAQ: IBRX). This inquiry focuses on potential securities fraud and other questionable business practices that may have impacted investors adversely.

On January 23, 2026, ImmunityBio released a press statement detailing significant results from the Phase 2 trial of its chemotherapy-free combination immunotherapy regimen for glioblastoma patients. Notably, the statement reflected that the primary endpoint of 'median overall survival' had not yet been reached, which raised red flags for many within the financial and medical communities. Following this announcement, ImmunityBio's stock witnessed a sharp decline, falling by $0.89 or approximately 12.13%, closing at $6.45 per share that day.

The firm is encouraging shareholders who have experienced financial losses attributed to these events to reach out to Danielle Peyton at Pomerantz LLP. They may have the opportunity to join a class action, which could empower them to seek restitution for the losses endured during this turbulent period.

Founded by the late Abraham L. Pomerantz, the firm holds a distinguished position in navigating the complexities of class action lawsuits, particularly in the sphere of securities. Over its 85-year history, Pomerantz has established a commendable track record in representing victims of fraud and corporate malpractice, leading to multi-million dollar recoveries for class members.

Legal experts are closely monitoring the unfolding situation at ImmunityBio. As a biopharmaceutical company, its developments may hold significant implications not just for investors but also for patients depending on its therapies. ImmunityBio has previously been under scrutiny due to the high stakes involved in drug development, particularly concerning clinical trials and the accuracy of reported results. Any missteps can affect investor confidence and the company’s market valuation.

The investigation comes at a crucial time for ImmunityBio as it navigates the complexities of clinical development and regulatory approval processes. With the current landscape of biotechnology being rife with both opportunity and risk, stakeholders are urged to remain vigilant.

For investors concerned about the implications of ImmunityBio's recent announcements and stock performance, legal avenues may be available through class action litigation. Pomerantz LLP's investigation is just one of many proactive measures that can safeguard investors’ rights amidst corporate uncertainty. Those interested in pursuing their claims can contact Pomerantz for further information.

In conclusion, ImmunityBio, Inc. finds itself at a crossroads following troubling clinical trial outcomes and significant stock price adjustments. Investors are recommended to stay informed about ongoing investigations and to explore their legal options to mitigate potential losses.